Cargando…

New proteasome inhibitors in the treatment of multiple myeloma

The treatment of patients with relapsed and/or refractory multiple myeloma has improved considerably in the last 15 years, after the introduction of proteasome inhibitors and immunomodulatory drugs. The first clinical trials with new proteasome inhibitors have produced exciting results, particularly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hungria, Vania Tietsche de Moraes, Crusoé, Edvan de Queiroz, Bittencourt, Rosane Isabel, Maiolino, Angelo, Magalhães, Roberto José Pessoa, Sobrinho, Jairo do Nascimento, Pinto, Jorge Vaz, Fortes, Ricardo Coutinho, Moreira, Eloisa de Sá, Tanaka, Paula Yurie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Hematologia e Hemoterapia 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371737/ https://www.ncbi.nlm.nih.gov/pubmed/30793108 http://dx.doi.org/10.1016/j.htct.2018.07.003

Ejemplares similares

Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012
por: Hungria, Vânia Tietsche de Moraes, et al.
Publicado: (2013)

Bilateral breast plasmacytoma: a clinical case report
por: Fischer, Thais Rodrigues da Cunha, et al.
Publicado: (2016)

Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira – 2022. Part I
por: Maiolino, Angelo, et al.
Publicado: (2022)

Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel – ABHH monoclonal gammopathies committe
por: Hungria, Vania, et al.
Publicado: (2020)

For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
por: Silva, Luiza Soares Vieira da, et al.
Publicado: (2017)

Multiple myeloma and central nervous system involvement: experience of a Brazilian center
por: Dias, Ana Luiza Miranda Silva, et al.
Publicado: (2018)

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2021)

Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life
por: Viol Ferreira Lopes, Maricy Almeida, et al.
Publicado: (2023)

COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM)
por: Garnica, Marcia, et al.
Publicado: (2021)

CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil
por: Hungria, Vania, et al.
Publicado: (2023)

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
por: Cury, Priscilla Cury de Camargo, et al.
Publicado: (2020)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
por: Crusoe, Edvan De Queiroz, et al.
Publicado: (2020)

Outcomes of autologous transplantation for multiple myeloma according to different induction regimens
por: de Queiroz Crusoe, Edvan, et al.
Publicado: (2014)

P954: MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY
por: Hungria, Vania, et al.
Publicado: (2023)

Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?
por: Crusoe, Edvan de Queiroz, et al.
Publicado: (2016)

Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies
por: Tietsche de Moraes Hungria, Vania, et al.
Publicado: (2016)

Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma()
por: Crusoé, Edvan de Queiroz, et al.
Publicado: (2021)

Lambda light chain-induced monoclonal gammopathy of renal significance, manifesting with Fanconi Syndrome and osteomalacia
por: Gutiérrez-Peredo, Gabriel Brayan, et al.
Publicado: (2022)

Oral health status of patients with multiple myeloma
por: Feitosa, Édila Figuerêdo, et al.
Publicado: (2020)

Can dentists detect multiple myeloma through oral manifestations?
por: Almeida, Thaís Miranda Xavier de, et al.
Publicado: (2018)

Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato‐Oncology (HOLA) Observational Study, 2008–2016
por: de Moraes Hungria, Vania Tietsche, et al.
Publicado: (2019)

PB1993: MULTIPLE MYELOMA BRAZILIAN REGISTER- HOW ABOUT THE TRANSPLANT ELIGIBLE PATIENTS?
por: Crusoe, E., et al.
Publicado: (2022)

Efficacy of a referral center for patient-centered care in multiple myeloma: a cohort study
por: Saccilotto, Indara C., et al.
Publicado: (2015)

P53: Stability from the Ubiquitin–Proteasome System and Specific 26S Proteasome Inhibitors
por: do Patrocinio, Andressa Barban, et al.
Publicado: (2022)

Novel strategies to target the ubiquitin proteasome system in multiple myeloma
por: Lub, Susanne, et al.
Publicado: (2015)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

Analysis of Proteasomal Proteolysis during the In Vitro Metacyclogenesis of Trypanosoma cruzi
por: Cardoso, Josiane, et al.
Publicado: (2011)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Knowledge and attitudes towards dementia in a sample of medical residents from a university-hospital in São Paulo, Brazil
por: Jacinto, Alessandro Ferrari, et al.
Publicado: (2016)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
por: Acosta-Alvear, Diego, et al.
Publicado: (2015)

Felis catus papillomavirus type-2 E6 binds to E6AP, promotes E6AP/p53 binding and enhances p53 proteasomal degradation
por: Altamura, Gennaro, et al.
Publicado: (2018)

Histoplasmosis of the Larynx
por: Pochini Sobrinho, Fernando, et al.
Publicado: (2015)

Reinterpretation of the nomenclatural type of Pseudobombax heteromorphum (Malvaceae, Bombacoideae) reveals an overlooked new species from Bolivia
por: de Carvalho-Sobrinho, Jefferson G., et al.
Publicado: (2013)

Epidemiological study of metabolic syndrome in Brazilian soldiers
por: Fortes, Marcos de Sá Rego, et al.
Publicado: (2019)

The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma
por: Op, Mélanie, et al.
Publicado: (2022)

Klotho increases antioxidant defenses in astrocytes and ubiquitin–proteasome activity in neurons
por: Orellana, Ana Maria, et al.
Publicado: (2023)

Modelling Proteasome and Proteasome Regulator Activities
por: Liepe, Juliane, et al.
Publicado: (2014)

Deubiquitination Reactions on the Proteasome for Proteasome Versatility
por: Shin, Ji Yeong, et al.
Publicado: (2020)

Effects of proteasome inhibitor MG-132 on the parasite Schistosoma mansoni
por: Morais, Enyara R., et al.
Publicado: (2017)

THE PANDEMIC OF COVID-19 AND THE TEACHING OF MICROSCOPIC ANATOMY: A PRACTICE USING VIRTUAL MICROSCOPY AND ONLINE CLASSES
por: Nascimento, Joao Pedro Santos, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l5cbrh2eq7qsk4k4iv4errrif5